La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Sage Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Sage Therapeutics..

Sage Therapeutics (NASDAQ:SAGE) Azioni, Catena delle Opzioni

SAGE THERAPEUTICS INC

Sage Therapeutics

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

Doctor,Utilizing,Advanced,Digital,Tablet,Technology,In,Modern,Healthcare.,Medical

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

SAGE

VERV

Settore in fermento: un&#39;analisi sulle aziende che stanno guidando la crescita. Scopri i segnali chiave per il tuo prossimo investimento.

Queste 3 azioni del settore sanitario stanno volando: ecco perché

Earnings

Earnings Beats

Sage Therapeutics Q2 EPS $(0.79) Beats $(0.93) Estimate, Sales $31.660M Beat $16.722M Estimate

6 analysts have expressed a variety of opinions on Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $9.37, a high estimate of $12.00, and a low estimate of $8.50. Observing a 0.43% increase, the current average has risen from the previous average price target of $9.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1751983239_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Sage Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$9.20</td>
<td>$12.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.50</td>
<td>$9.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$9.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$8.50</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sage Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sage Therapeutics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Sage Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Sage Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SAGE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Sage Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Sage Therapeutics</h2>
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
<h3>Understanding the Numbers: Sage Therapeutics's Finances</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Sage Therapeutics's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 77.97%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Sage Therapeutics's net margin excels beyond industry benchmarks, reaching -442.39%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Sage Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -14.22%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Sage Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -12.24%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Sage Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.03.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Beyond The Numbers: 6 Analysts Discuss Sage Therapeutics Stock

Scotiabank analyst George Farmer downgrades Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) from Sector Outperform to Sector Perform and lowers the price target from $12 to $9.2.

Downgrades

Price Target

Scotiabank Downgrades Sage Therapeutics to Sector Perform, Lowers Price Target to $9.2

Baird analyst Joel Beatty maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Neutral and raises the price target from $7 to $9.

Baird Maintains Neutral on Sage Therapeutics, Raises Price Target to $9

Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $9.5, a high estimate of $12.00, and a low estimate of $8.50. This current average reflects an increase of 2.7% from the previous average price target of $9.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1750186823_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Sage Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.50</td>
<td>$9.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$9.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$8.50</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Sage Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sage Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Sage Therapeutics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Sage Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SAGE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Sage Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Sage Therapeutics</h2>
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
<h3>Sage Therapeutics: Financial Performance Dissected</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Sage Therapeutics's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 77.97%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Sage Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -442.39%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Sage Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -14.22%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -12.24%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Sage Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.03.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Sage Therapeutics Stock: Analyst Perspectives (4 Ratings)

Supernus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) on Monday agreed to acquire Sage Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) for $12.00 per share in cash, or an aggregate of up to approximately $795 million.
The deal consideration includes $8.50 per share in cash (or an aggregate of approximately $561 million) plus one non-tradable contingent value right (CVR) collectively worth up to $3.50 per share in cash (or an aggregate of approximately $234 million).
"This acquisition represents a major step in bolstering our future growth. It augments our growth profile by adding a significant fourth growth product to our portfolio and further diversifies our sources of future growth. Zurzuvae aligns with our focus of acquiring novel value-enhancing and clinically differentiated medicines to treat CNS conditions," said Jack Khattar, president and CEO of Supernus Pharmaceuticals.
Sage Therapeutics shares gained 0.4% to trade at $9.11 on Tuesday.
These analysts made changes to their price targets on Sage Therapeutics following acquisition announcement.
<ul class="wp-block-list">
<li>Canaccord Genuity analyst Sumant Kulkarni maintained Sage Therapeutics with a Hold and raised the price target from $8 to $8.5.</li>
<li>Truist Securities analyst Joon Lee maintained the stock with a Hold and raised the price target from $8 to $9.</li>
<li>Piper Sandler analyst David Amsellem downgraded Sage Therapeutics from Overweight to Neutral and lowered the price target from $9 to $8.5.</li>
</ul>
Considering buying SAGE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/SAGE/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="574" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17142045/image-267-1024x574.png" alt="" class="wp-image-952816" style="width:612px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17142045/image-267-1024x574.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17142045/image-267-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17142045/image-267-768x430.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17142045/image-267.png 1137w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/06/45973780/nvidia-to-rally-more-than-38-here-are-10-top-analyst-forecasts-for-tuesday">Nvidia To Rally More Than 38%? Here Are 10 Top Analyst Forecasts For Tuesday</a> </li>
</ul>
Photo via Shutterstock

SUPN

These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News

Piper Sandler analyst David Amsellem downgrades Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) from Overweight to Neutral and lowers the price target from $9 to $8.5.

Piper Sandler Downgrades Sage Therapeutics to Neutral, Lowers Price Target to $8.5

Truist Securities analyst Joon Lee maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Hold and raises the price target from $8 to $9.

Truist Securities Maintains Hold on Sage Therapeutics, Raises Price Target to $9

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Neutral and maintains $12 price target.

Reiteration

HC Wainwright & Co. Reiterates Neutral on Sage Therapeutics, Maintains $12 Price Target

As of June 17, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Regencell Bioscience Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>)</h3>
<ul class="wp-block-list">
<li>Regencell Bioscience's 38-for-one forward stock split officially took effect on Monday. The split, announced at the beginning of June and distributed on June 13, gave shareholders 37 additional shares for each one they already owned. The stock began trading on a split-adjusted basis on Monday. The company stated that the goal of the split was to improve liquidity and make its shares more accessible to investors. The company's stock jumped around 548% over the past month and has a <a href="https://www.benzinga.com/quote/RGC">52-week high of $83.60</a>.</li>
<li>RSI Value: 94&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>RGC Price Action: Shares of Regencell Bioscience gained 276.2% to close at $60.00 on Monday.</li>
<li>Edge Stock Ratings: 91.92 Momentum score with Value at 93.51.</li>
</ul>
<h3 class="wp-block-heading">Verve Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>)</h3>
<ul class="wp-block-list">
<li>On May 14, Verve Therapeutics reported a year-over-year increase for first-quarter EPS results. &#8220;2025 is off to a strong start with both clinical and regulatory progress. Last month, we reported exciting initial data from the Heart-2 clinical trial, which demonstrated that a single infusion of VERVE-102, a base editing medicine targeting PCSK9, was well-tolerated and led to compelling, dose-dependent reductions in LDL-C. These data, along with ongoing durability data of up to two years from our Heart-1 clinical trial, suggest a product profile that could fundamentally transform the journey for patients living with cardiovascular disease from decades of chronic care to a one dose future,&#8221; said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve Therapeutics. The company's stock gained around 43% over the past month and<a href="https://www.benzinga.com/quote/VERV"> has a 52-week high</a> of $9.30.</li>
<li>RSI Value: 88.1</li>
<li>VERV Price Action: Shares of Verve Therapeutics rose 1.8% to close at $6.27 on Monday.</li>
</ul>
<h3 class="wp-block-heading">SAGE Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>)</h3>
<ul class="wp-block-list">
<li>On June 16, Supernus Pharmaceuticals agreed to acquire Sage Therapeutics for $12.00 per share in cash, or an aggregate of up to approximately $795 million. The deal consideration includes $8.50 per share in cash (or an aggregate of approximately $561 million) plus one non-tradable contingent value right (CVR) collectively worth up to $3.50 per share in cash (or an aggregate of approximately $234 million). The company's stock gained around 32% over the past five days and has a <a href="https://www.benzinga.com/quote/SAGE">52-week high </a>of $13.46.</li>
<li>RSI Value: 86.2</li>
<li>SAGE Price Action: Shares of SAGE Therapeutics gained 35.4% to close at $9.07 on Monday.</li>
</ul>
Learn more about BZ Edge Rankings—click to see scores for other <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">stocks in the sector and see how they compare.</a>
Read This Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45948533/top-2-financial-stocks-that-may-plunge-in-q2"> Top 2 Financial Stocks That May Plunge in Q2</a></li>
</ul>

Top 3 Health Care Stocks That Are Ticking Portfolio Bombs

Canaccord Genuity analyst Sumant Kulkarni maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Hold and raises the price target from $8 to $8.5.

Canaccord Genuity Maintains Hold on Sage Therapeutics, Raises Price Target to $8.5

U.S. stock futures were trading lower on Tuesday following Monday&#8217;s advance. Futures of major benchmark indices were lower in premarket.
President Donald Trump called on <a href="https://www.benzinga.com/news/events/25/06/45964856/trump-asks-everyone-to-immediately-evacuate-tehran-odds-of-us-striking-iran-spike-on-crypto-betting-platform">Iranians to leave Tehran</a>, pointing to the government&#8217;s refusal to accept a deal aimed at limiting nuclear weapons development, amid ongoing attacks between Israel and Iran that marked the fifth consecutive day on Tuesday.
At the G7 summit in Canada, world leaders urged a reduction in tensions during the most severe clash ever between these regional adversaries, labeling Iran as a source of instability and insisting it must never acquire nuclear weapons, while also recognizing Israel&#8217;s right to self-defense.
Trump took to Truth Social on Monday to clarify his abrupt departure from the G7 Summit in Canada. He refuted Macron's claim that he was returning to Washington to negotiate a ceasefire between Israel and Iran. "He has no idea why I am now on my way to Washington, but it certainly has nothing to do with a Cease Fire. Much bigger than that," Trump wrote.
Trump had previously urged citizens of Tehran, Iran's capital, to evacuate immediately, indicating a potential U.S. involvement in the conflict.
Meanwhile, President Trump, while on Air Force One returning from the G-7 summit, told reporters he is seeking <a href="https://www.benzinga.com/markets/equities/25/06/45968002/trump-says-israel-iran-ceasefire-not-on-the-table-left-g7-early-for-a-much-bigger-reason-spy-qqq">&#8220;a real end&#8221; to Iran&#8217;s nuclear issue</a>, with Tehran giving it up &#8220;entirely.&#8221;
The 10-year Treasury bond yielded 4.43% and the two-year bond was at 3.96%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>&#8216;s projections show markets pricing a 99.9% likelihood of the Federal Reserve keeping the current interest rates unchanged in its June meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.59%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.54%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.46%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.94%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell in premarket on Tuesday. The SPY was down 0.54% at $599.42, while the QQQ declined 0.58% to $531.18, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
Communication services, information technology, and consumer discretionary stocks recorded the biggest gains on Monday, leading most sectors on the S&amp;P 500 to close on a positive note, while utilities and health care stocks bucked the overall market trend, ending the session lower.
Sage Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares surged over 35% on Monday following Supernus Pharmaceuticals&#8217; agreement to acquire the company.
Conversely, shares of Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) dropped more than 42% after the company halted ELEVIDYS shipments and paused the ENVISION trial due to a second fatal liver failure in non-ambulatory Duchenne patients.
On the economic front, the New York Empire State Manufacturing Index fell to a reading of -16 in June, down from May's figure of -9.2 and below market expectations of -5.5.
The Dow Jones index ended 317 points or 0.75% higher at 42,515.09, whereas the S&amp;P 500 index rose 0.94% to 6,033.11. Nasdaq Composite advanced 1.52% to 19,701.21, and the small-cap gauge, Russell 2000, gained 1.12% to end at 2,124.13.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>1.52%</td>
<td>19,701.21</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.94%</td>
<td>6,033.11</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.75%</td>
<td>42,515.09</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.12%</td>
<td>2,124.13</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Despite the dominating geopolitical headlines, a senior economist at WisdomTree, Jeremy Siegel, told investors that they need to focus on the more meaningful development: &#8220;the continued softening of inflation data.&#8221;
&#8220;Both CPI and PPI came in on the low side, confirming the disinflationary trend that's been evident. These price increases have not yet fully worked their way into the data and are likely to show up over the next couple of months. Even so, the underlying trend is down (excluding tariff impacts coming up). My view remains firm: ex-tariffs, inflation is cooling, and the Fed should begin easing policy,&#8221; he said.
He said that he remains &#8220;optimistic&#8221; about the stock market. &#8220;Markets have shown impressive resilience, inflation is heading in the right direction, and the Fed will ultimately come along. Stay focused on fundamentals and avoid getting whipsawed by noise,&#8221; he added.
Meanwhile, Jeff Buchbinder, the chief equity strategist at LPL Financial explained that there are several key questions to answer before we know how stocks will handle this geopolitical shock, including how much of Iran's energy infrastructure will be impaired and for how long, whether Iran's nuclear capabilities will be completely wiped out, and whether the current regime will remain in power.
For those surprised that the U.S. stock market held up well on Monday, Buchbinder argued that it was a combination of several factors:
<ul class="wp-block-list">
<li>The likelihood of regime change in Iran and a resulting "peace dividend",</li>
<li>U.S. energy independence,</li>
<li>Israel's interest in limiting the suffering of Iranian civilians (which could mean limited disruption to oil production facilities), and</li>
<li>Both players have limited resources and an interest in keeping the conflict contained.</li>
</ul>
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures</a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Tuesday:
<ul class="wp-block-list">
<li>May&#8217;s U.S. retail sales and import price index will be out by 8:30 a.m. ET.</li>
<li>May&#8217;s industrial production and capacity utilization will be announced by 9:15 a.m. ET.</li>
<li>April Business inventories data and June&#8217;s home builder confidence index data will be released at 10:00 a.m. ET.</li>
</ul>
Stocks In Focus:
<ul class="wp-block-list">
<li>Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) was up 0.65% in premarket on Tuesday as analysts expect it to report quarterly earnings of $2.31 per share on revenue of $7.06 billion, before the opening bell.</li>
<li>John Wiley &amp; Sons Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLY#NYSE">WLY</a>) advanced 2.03% ahead of its earnings, which are supposed to be released before the opening bell. Analysts expect earnings of $1.27 per share on revenue of $434.90 million.</li>
<li>La-Z-Boy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LZB#NYSE">LZB</a>) declined 0.077% as analysts expect it to report quarterly earnings of 93 cents per share on revenue of $557.44 million, after the closing bell.</li>
<li>Globus Maritime Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBS#NASDAQ">GLBS</a>) dropped 3.91% after posting downbeat results for the first quarter on Monday. The company reported a quarterly loss of 7 cents per share, compared to market estimates of a loss of 3 cents per share.</li>
<li>Lennar Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) was up 2.70% after reporting mixed results for the second quarter after Monday's closing bell.</li>
<li>Digital Turbine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPS#NASDAQ">APPS</a>) jumped 6.86% after it reported quarterly earnings of 10 cents per share, which beat the analyst consensus estimate of four cents.</li>
<li>High Tide Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HITI#NASDAQ">HITI</a>) edged 2.67% higher after it reported second-quarter revenue of $96.94 million versus estimates of $96.73 million, up 11% year-over-year.</li>
<li>Redwire Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) plunged 9.14% after it announced a $200 million registered public offering of common stock.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 1.48% to hover around $71.29 per barrel.
Gold Spot US Dollar fell 0.18% to hover around $3,379.21 per ounce. Its last record high stood at $3,500.33 per ounce. The U.S. Dollar Index spot was higher by 0.19% at the 98.1870 level.
Asian markets ended mixed on Tuesday as South Korea's Kospi and Japan's Nikkei 225 indices rose. While China&#8217;s CSI 300, Hong Kong's Hang Seng, Australia's ASX 200, and India's S&amp;P BSE Sensex indices declined. European markets were lower in early trade.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45967469/us-equity-funds-are-raking-in-billions-these-are-the-ones-beating-trumps-tariff-shock-in-2025">US Equity Funds Are Raking In Billions—These Are The Ones Beating Trump&#8217;s Tariff Shock in 2025</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

APPS

GLBS

HITI

SRPT

US Stock Futures Tumble After Trump Threatens 'Real End' To Iran's Nuclear Problem: '…Avoid Getting Whipsawed By Noise,' Says Expert

The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, while the index remained in the &#8220;Greed&#8221; zone on Monday.
U.S. stocks settled higher on Monday, with the Dow Jones index gaining more than 300 points during the session after Iran signaled it wants to de-escalate tensions with Israel and return to negotiations, easing geopolitical jitters that had rattled investors and sent oil prices surging last week.
Sage Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares surged over 35% on Monday after Supernus Pharmaceuticals agreed to acquire the company. Shares of Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) dipped more than 42% after the company suspended ELEVIDYS shipments and paused the ENVISION trial following a second fatal liver failure in non-ambulatory Duchenne patients.
On the economic front, the New York Empire State Manufacturing Index dipped to a reading of -16 in June compared to May&#8217;s reading of -9.2, and also down from market estimates of -5.5.
Most sectors on the S&amp;P 500 closed on a positive note, with communication services, information technology and consumer discretionary stocks recording the biggest gains on Monday. However, utilities and health care stocks bucked the overall market trend, closing the session lower.
The Dow Jones closed higher by around 317 points to 42,515.09 on Monday. The S&amp;P 500 gained 0.94% to 6,033.11, while the Nasdaq Composite climbed 1.52% to 19,701.21 during Monday's session.
Investors are awaiting earnings results from Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>), John Wiley &amp; Sons Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLY#NYSE">WLY</a>) and La-Z-Boy Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LZB#NYSE">LZB</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 62, the index remained in the &#8220;Greed&#8221; zone on Monday, versus a prior reading of 60.3.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45948533/top-2-financial-stocks-that-may-plunge-in-q2">Top 2 Financial Stocks That May Plunge in Q2</a> </li>
</ul>
Photo via Shutterstock

Dow Surges Over 300 Points As Iran Signals De-Escalation: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone

U.S. stocks traded higher midway through trading, with the S&amp;P 500 gaining around 1% on Monday.
The Dow traded up 0.80% to 42,536.72 while the NASDAQ climbed 1.51% to 19,699.21. The S&amp;P 500 also rose, gaining, 0.97% to 6,034.20.
Check This Out: <a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/06/45948648/this-boston-scientific-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-monday">This Boston Scientific Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday</a>
Leading and Lagging Sectors Financial shares jumped by 1.7% on Monday.
In trading on Monday, energy stocks fell by 0.6%.
Top Headline
The New York Empire State Manufacturing Index dipped to a reading of -16 in June compared to May's reading of -9.2, and also down from market estimates of -5.5.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Sage Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares shot up 35% to $9.02 after Supernus Pharmaceuticals agreed to acquire the company.</li>
<li>Shares of SRM Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRM#NASDAQ">SRM</a>) got a boost, surging 293% to $5.68 after the company entered a securities purchase agreement with a private investor for a $100 million equity investment, which it will use to initiate a TRON token treasury strategy.</li>
<li>EchoStar Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATS#NASDAQ">SATS</a>) shares were also up, gaining 47% to $24.78 after President Trump reportedly urged Ergen and Carr to cut a deal on the company&#8217;s spectrum.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Robin Energy Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBNE#NASDAQ">RBNE</a>) shares dropped 56% to $6.17. Robin Energy announced pricing of $5.1 million registered direct offering priced at-the-market under Nasdaq rules.</li>
<li>Shares of Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) were down 47% to $19.15 after the company suspended ELEVIDYS shipments and paused the ENVISION trial following a second fatal liver failure in non-ambulatory Duchenne patients.</li>
<li>LZ Technology Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LZMH#NASDAQ">LZMH</a>) was down, falling 24% to $12.30.</li>
</ul>
Commodities In commodity news, oil traded down 4% to $70.06 while gold traded down 1.2% at $3,413.10.
Silver traded up 0.1% to $36.38 on Monday, while copper rose 0.2% to $4.8245.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.50%, while Spain's IBEX 35 Index rose 1.41%. London's FTSE 100 gained 0.43%, Germany's DAX 40 rose 0.71% and France's CAC 40 climbed 0.92% during the session.
Asia Pacific Markets
Asian markets closed higher on Monday, with Japan's Nikkei gaining 1.26%, Hong Kong's Hang Seng Index rising 0.70%, China's Shanghai Composite rising 0.35% and India's BSE Sensex climbing 0.84%.
Economics
The New York Empire State Manufacturing Index dipped to a reading of -16 in June compared to May's reading of -9.2, and also down from market estimates of -5.5.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45946608/top-3-materials-stocks-that-could-blast-off-this-month-3">Top 3 Materials Stocks That Could Blast Off This Month</a> </li>
</ul>
Photo via Shutterstock

Eurozone

Commodities

LZMH

RBNE

SATS

S&P 500 Surges 1%; New York Manufacturing Activity Tumbles In June

<h3>Gainers</h3>
<ul>
<li>Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares moved upwards by 35.7% to $9.1 during Monday's regular session. The market value of their outstanding shares is at $569.5 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock moved upwards by 30.04% to $0.03. The market value of their outstanding shares is at $10.7 million. </li>
<li>Immuneering (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) stock moved upwards by 18.94% to $2.26. The market value of their outstanding shares is at $81.3 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock increased by 18.01% to $0.14. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) stock increased by 17.68% to $3.86. The market value of their outstanding shares is at $28.7 million. </li>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) shares moved upwards by 17.47% to $1.21. The company's market cap stands at $18.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shares decreased by 44.8% to $19.96 during Monday's regular session. The market value of their outstanding shares is at $1.9 billion. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock decreased by 27.34% to $0.37. </li>
<li>NextCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTC#NASDAQ">NXTC</a>) stock fell 26.72% to $0.5. The company's market cap stands at $13.9 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares decreased by 19.98% to $0.33. The market value of their outstanding shares is at $7.8 million. </li>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares declined by 18.89% to $1.16. The market value of their outstanding shares is at $20.3 million. </li>
<li>OKYO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKYO#NASDAQ">OKYO</a>) stock fell 15.95% to $2.53. The market value of their outstanding shares is at $85.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CYCC

GOVX

HCTI

HSDT

IMNN

IMRX

NCNA

NXTC

OKYO

12 Health Care Stocks Moving In Monday's Intraday Session

U.S. stocks were higher, with the Dow Jones index gaining around 500 points on Monday.
Shares of Sage Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) rose sharply during Monday's session after Supernus Pharmaceuticals <a href="https://www.benzinga.com/quote/SAGE">agreed to acquire the company</a>.
Supernus Pharmaceuticals on Monday agreed to acquire Sage Therapeutics for $12.00 per share in cash, or an aggregate of up to approximately $795 million.
The deal consideration includes $8.50 per share in cash (or an aggregate of approximately $561 million) plus one non-tradable contingent value right (CVR) collectively worth up to $3.50 per share in cash (or an aggregate of approximately $234 million).
Sage Therapeutics shares climbed 35.6% to $9.09 on Monday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>EchoStar Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATS#NASDAQ">SATS</a>) shares jumped 48.2% to $24.96 after President Trump reportedly urged Ergen and Carr to cut a deal on the company&#8217;s spectrum.</li>
<li>AIRO Group Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRO#NASDAQ">AIRO</a>) jumped 42% to $31.11 after jumping 140% on Friday. AIRO Group priced its $60 million initial public offering of 6 million common shares at $10 per share.</li>
<li>Circle Internet Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRCL#NYSE">CRCL</a>) gained 22.1% to $163.13.</li>
<li>Arqit Quantum Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQQ#NASDAQ">ARQQ</a>) rose 21% to $28.77.</li>
<li>NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) gained 17.4% to $35.83. NANO Nuclear Energy announced that Matthew Barry has joined the Company as its Director of Investor Relations.</li>
<li>TSS, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSSI#NASDAQ">TSSI</a>) rose 17.4% to $21.63.</li>
<li>TMC the metals company Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>) rose 17.1% to $5.08 after Korea Zinc announced an equity investment of $85.2 million in the company.</li>
<li>UroGen Pharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) climbed 17% to $14.05.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) surged 15.6% to $19.17.</li>
<li>NextNav Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NN#NASDAQ">NN</a>) gained 15.6% to $14.88.</li>
<li>Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) rose 10.3% to $82.06 after the company announced a new integration with Amazon Ads.</li>
<li>Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) gained 10.2% to $61.17.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) rose 10% to $42.21.</li>
<li>Uranium Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UEC#NYSE">UEC</a>) gained 9.8% to $6.87.</li>
<li>Newell Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) rose 9.5% to $5.74.</li>
<li>Darling Ingredients Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAR#NYSE">DAR</a>) gained 9.1% to $39.28. Darling Ingredients announced offering of €750 Million of senior notes by Darling Global Finance B.V. and proposed entry into a new amended and restated credit agreement.</li>
<li>MP Materials Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>) rose 9% to $33.42.</li>
<li>Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) surged 8.5% to $126.01.</li>
<li>The Estée Lauder Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) gained 7.9% to $72.67.</li>
<li>Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) climbed 6% to $71.15. Marvell Technology announced a quarterly dividend of 6 cents per share of common stock.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45946608/top-3-materials-stocks-that-could-blast-off-this-month-3">Top 3 Materials Stocks That Could Blast Off This Month</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

AIRO

ARQQ

ASTS

CRCL

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MRVL

QUBT

ROKU

TSSI

URGN

Sage Therapeutics, Roku, EchoStar And Other Big Stocks Moving Higher On Monday

Supernus Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) on Monday agreed to acquire Sage Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) for $12.00 per share in cash, or an aggregate of up to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45945434/supernus-pharmaceuticals-to-acquire-sage-therapeutics-strengthening-its-neuropsychiatry-product-po" rel="noreferrer noopener">approximately $795 million</a>.
The deal consideration includes $8.50 per share in cash (or an aggregate of approximately $561 million) plus one non-tradable contingent value right (CVR) collectively worth up to $3.50 per share in cash (or an aggregate of approximately $234 million).
The CVR is payable upon achieving certain net sales and commercial milestones. The transaction is expected to close in the third quarter of 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43815436/supernus-pharmaceuticals-stock-falls-on-disappointing-data-from-treatment-resistant-depression-trial" rel="noreferrer noopener">Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial</a>
<h2 class="wp-block-heading">Strategic and Financial Benefits</h2>
The acquisition significantly strengthens Supernus Pharmaceuticals&#8217; psychiatry portfolio by adding Zurzuvae (zuranolone) capsules CIV, a landmark drug that stands as the first and only oral medicine approved by the FDA for treating postpartum depression in adults.
This strategic addition is set to diversify and substantially increase Supernus Pharmaceuticals&#8217; revenue base and cash flow. The financial impact is already evident from the collaboration revenue derived from Zurzuvae&#8217;s net sales, which, representing 50% of the net revenue recorded by Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), amounted to $36.1 million for the full year 2024 and $13.8 million in the first quarter of 2025 alone.
Supernus believes that with Zurzuvae joining its three other key growth products, Qelbree, ONAPGO, and GOCOVRI, the company is poised for significant future growth.
Beyond the immediate commercial benefits, the deal also augments Supernus Pharmaceuticals&#8217; central nervous system (CNS) discovery platforms and deepens its expertise in the field.
Furthermore, the strong integration potential with Supernus Pharmaceuticals&#8217; existing infrastructure is expected to yield substantial operational efficiencies, with projected annual cost synergies of up to $200 million.
&#8220;This acquisition represents a major step in bolstering our future growth. It augments our growth profile by adding a significant fourth growth product to our portfolio and further diversifies our sources of future growth. Zurzuvae aligns with our focus of acquiring novel value-enhancing and clinically differentiated medicines to treat CNS conditions,&#8221; said Jack Khattar, president and CEO of Supernus Pharmaceuticals.
In a significant development <a href="https://www.benzinga.com//node/42957657">preceding the acquisition</a> by Supernus Pharmaceuticals, Biogen Inc. had made an unsolicited, non-binding proposal to acquire all of the outstanding shares of Sage Therapeutics that it did not already own. The offer was made on January 10, 2025, for a price of $7.22 per share.
In October 2024, Sage Therapeutics announced a strategic reorganization of its business operations to support the ongoing launch of Zurzuvae (zuranolone)&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41376682/sage-therapeutics-announces-strategic-reorganization-to-prioritize-zurzuvae-commercialization-and-" rel="noreferrer noopener">in postpartum depression</a>.
The company said the reorganization was intended to strengthen Sage&#8217;s balance sheet, extend its cash runway, and position the company for long-term growth potential.
The company&#8217;s layoff impacted over 165 employees (approximately 33% of its total workforce and approximately 55% of its R&amp;D workforce), including changes to&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41382549/after-series-of-trial-setbacks-sage-therapeutics-to-lay-off-one-third-workforce" rel="noreferrer noopener">the leadership team</a>.
In September 2024, Biogen terminated its rights under the collaboration and license agreement with Sage, which was specific to the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41049022/biogen-terminates-collaboration-with-sage-therapeutics-for-neurological-disorder-candidate" rel="noreferrer noopener">SAGE-324 program</a>.
Price Action: SAGE stock was trading higher by 36.3% to $9.13 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/03/44190052/johnson-johnson-stops-late-stage-depression-study-over-insufficient-efficacy" target="_blank" rel="noreferrer noopener">Johnson &amp; Johnson Stops Late-Stage Depression Study Over &#8216;Insufficient Efficacy&#8217;</a></li>
</ul>
Photo Courtesy: S Prodution on Shutterstock.com

Biotech

Health Care

General

BIIB

Supernus Pharma Acquires Maker Of Postpartum Depression Drug Zurzuvae In $795 Million Deal

Needham analyst Ami Fadia reiterates Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) from Hold to Hold.

Needham Reiterates Hold on Sage Therapeuticsto Hold

<h3>Gainers</h3>
<ul>
<li>Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares rose 37.5% to $9.21 during Monday's pre-market session. The company's market cap stands at $576.7 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares increased by 37.43% to $0.03. The company's market cap stands at $11.3 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares increased by 20.58% to $0.39. The company's market cap stands at $11.8 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares increased by 17.21% to $5.48. The market value of their outstanding shares is at $2.8 million. </li>
<li>HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) shares rose 15.89% to $1.75. The market value of their outstanding shares is at $59.1 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares rose 15.49% to $0.13. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) stock decreased by 39.8% to $21.79 during Monday's pre-market session. The market value of their outstanding shares is at $2.1 billion. </li>
<li>Jupiter Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JUNS#NASDAQ">JUNS</a>) stock decreased by 11.51% to $1.0. The market value of their outstanding shares is at $33.1 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) shares fell 11.21% to $0.32. The company's market cap stands at $4.0 million. </li>
<li>Co-Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) stock declined by 9.36% to $0.25. The company's market cap stands at $8.4 million. </li>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) stock declined by 7.69% to $1.32. The market value of their outstanding shares is at $23.1 million. </li>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) stock fell 7.39% to $0.61. The company's market cap stands at $5.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APDN

BEAT

BFRI

CODX

JUNS

ONMD

VTAK

12 Health Care Stocks Moving In Monday's Pre-Market Session

WIIM

Sage Therapeutics shares are trading higher after Supernus Pharmaceuticals agreed to acquire the company.

Press Releases

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HONE, FL, SAGE on Behalf of Shareholders

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: CARM, GNTY, TSBX, and SAGE

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAGE, COEP, AVDX on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVEE, SAGE, OLO on Behalf of Shareholders

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAGE, CHTR, VIGL on Behalf of Shareholders

ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression

Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer

Comments

Sage Therapeutics

Sage Therapeutics (SAGE) Opzioni

Sage Therapeutics (NASDAQ:SAGE) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO